```html

Zollinger‑Ellison Syndrome (Gastrinoma with Liver Metastasis)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine tumor (NET) that originates in the G‑cells of the pancreas or duodenum and secretes excessive amounts of gastrin. The resulting hypergastrinemia stimulates the stomach to produce large volumes of acid, leading to severe peptic ulcer disease and diarrhea. Approximately 20–30 % of gastrinomas have already spread to the liver at the time of diagnosis, classifying the disease as metastatic.

Who it affects: ZES can occur at any age but most patients are diagnosed between 30 and 60 years. There is a slight male predominance (≈55 % male). About 25 % of cases are associated with the hereditary condition multiple endocrine neoplasia type 1 (MEN‑1), which increases the risk of multiple endocrine tumors.

Prevalence: Gastrinomas account for <1 % of all pancreatic tumors and an estimated 0.5–2 cases per million people per year worldwide (NIH, 2023). Because many are small and asymptomatic, the true prevalence may be higher.

Symptoms

Symptoms arise from two main mechanisms: (1) excess gastric acid and (2) the tumor’s local or metastatic effects.

Gastro‑intestinal symptoms

• Refractory peptic ulcers – often multiple, large, or located beyond the duodenum (e.g., jejunal ulcers).
• Abdominal pain – burning or cramping pain that may improve with meals (due to ulcer healing) but can also worsen.
• Diarrhea – watery, often 3–8 stools/day; may be greasy if fat malabsorption occurs.
• Steatorrhea – foul‑smelling, pale stools caused by bile salt inactivation from high acid.
• Nausea & vomiting – especially after large meals.

Systemic and metabolic symptoms

• Weight loss – secondary to malabsorption and chronic diarrhea.
• Fatigue – from anemia (chronic bleeding) or malnutrition.
• Hypokalemia & metabolic alkalosis – due to volume depletion from diarrhea.

Symptoms related to liver metastasis

• Right‑upper‑quadrant discomfort or fullness – caused by enlarging hepatic lesions.
• Jaundice – if a metastasis obstructs bile ducts.
• Elevated liver enzymes – often discovered incidentally on labs.
• Unexplained fever or night sweats – rare but may signal tumor activity.

Causes and Risk Factors

Underlying cause

ZES is caused by a somatic or germline mutation that leads to uncontrolled gastrin secretion. The majority are sporadic; about one‑quarter are linked to MEN‑1, a hereditary syndrome caused by mutations in the MEN1 tumor suppressor gene.

Risk factors

• Family history of MEN‑1 or other endocrine neoplasias.
• Previous pancreatic or duodenal neuroendocrine tumors.
• Chronic atrophic gastritis – can increase gastrin levels but does not cause ZES.
• Smoking – associated with a modestly higher risk of neuroendocrine tumors.
• Age ≥ 30 years – incidence rises sharply after this age.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is essential, especially when ulcers are refractory or multiple.

Laboratory tests

• Fasting serum gastrin – levels > 1000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when gastric pH < 2.
• Secretin stimulation test – a rise in gastrin > 200 pg/mL after IV secretin confirms ZES (most sensitive test).
• Chromogranin A – elevated in many NETs; useful for monitoring disease burden.
• Liver function panel – to detect metastasis‑related abnormalities.

Imaging studies

• Contrast‑enhanced CT or MRI abdomen – first‑line to locate primary tumor and assess hepatic metastases (sensitivity 70–85 %).
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – highly sensitive for NETs and guides peptide‑receptor radionuclide therapy (PRRT).
• Endoscopic ultrasound (EUS) – excellent for detecting small (< 1 cm) pancreatic lesions and allows fine‑needle aspiration for histology.
• Selective arterial secretagogue injection (SASI) test – used when non‑invasive imaging is inconclusive.

Pathology

Biopsy of the primary or metastatic lesion shows well‑differentiated neuroendocrine cells positive for gastrin, chromogranin A, and synaptophysin. Ki‑67 labeling index helps grade the tumor (G1‑G3).

Treatment Options

Management targets two goals: control of gastric acid hypersecretion and eradication or control of the tumor.

Acid‑suppression therapy (essential for all patients)

• High‑dose proton pump inhibitors (PPIs) – omeprazole 60–80 mg/day or equivalent; titrate to maintain gastric pH > 4 (Mayo Clinic, 2022).
• Histamine‑2 receptor antagonists (H2RAs) – used adjunctively only if PPIs insufficient.
• Long‑term PPI therapy is usually lifelong; monitor for vitamin B12 deficiency, magnesium loss, and osteoporosis.

Surgical treatment

• Curative resection – preferred for localized gastrinomas (pancreaticoduodenectomy or enucleation).
• Debulking surgery – removal of > 90 % of tumor bulk, including hepatic metastases, can improve symptoms and survival.
• In MEN‑1 patients, surgery is more selective because of multifocal disease; options include duodenotomy with tumor excision.

Medical therapy for tumor control

• Somatostatin analogues (octreotide LAR, lanreotide) – bind somatostatin receptors, inhibit gastrin release, and may shrink metastases.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive, unresectable disease.
• Peptide‑receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to receptor‑positive cells; improves progression‑free survival (NETTER‑1 trial, 2021).
• Chemotherapy – reserved for high‑grade (G3) or rapidly progressive tumors; regimens often include streptozocin, 5‑fluorouracil, or temozolomide.

Local therapies for liver metastases

• Radiofrequency ablation (RFA) or microwave ablation – percutaneous destruction of small hepatic lesions.
• Trans‑arterial embolization (TAE) / chemoembolization (TACE) – reduces tumor blood supply, palliates symptoms.
• Liver transplantation – considered only in highly selected patients with unresectable disease confined to the liver and no extra‑hepatic spread.

Lifestyle and supportive measures

• Eat small, frequent meals; avoid large fatty meals that stimulate acid.
• Stay hydrated; replace electrolytes (especially potassium and magnesium) if diarrhea is severe.
• Quit smoking and limit alcohol, both of which can aggravate ulcer disease.
• Regular bone‑density testing if on long‑term high‑dose PPIs.

Living with Zollinger‑Ellison Syndrome (Gastrinoma with Liver Metastasis)

Daily management tips

• Medication adherence – set alarms for PPIs and somatostatin analogues; never skip doses.
• Monitor stool pattern – keep a diary of frequency, consistency, and any blood; report changes promptly.
• Nutrition – high‑protein, low‑fat diet; consider medium‑chain triglyceride (MCT) oil to improve fat absorption without overwhelming bile salts.
• Supplements – vitamin B12 (1000 µg monthly), calcium + vitamin D, and a multivitamin if on PPIs > 1 year.
• Regular follow‑up – labs every 3–6 months (gastrin, chromogranin A, liver panel) and imaging every 6–12 months to monitor disease.
• Psychosocial support – join NET patient groups, consider counseling to cope with chronic illness.

What to discuss with your healthcare team

• Potential side effects of long‑term PPI and somatostatin analogue therapy.
• Eligibility for clinical trials (e.g., new PRRT protocols).
• Family screening if MEN‑1 is suspected; genetic counseling is recommended.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling for individuals with a family history of MEN‑1; early detection can lead to surveillance and earlier intervention.
• Avoid chronic Helicobacter pylori infection – while not a direct cause, eradication reduces background ulcer disease.
• Healthy lifestyle – smoking cessation, moderate alcohol use, and a balanced diet lower overall cancer risk.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems:

• Recurrent or perforated peptic ulcers – may cause peritonitis, bleeding, or need for emergency surgery.
• Severe malabsorption – leading to protein‑calorie deficiency, anemia, and osteoporosis.
• Electrolyte disturbances – chronic diarrhea can cause hypokalemia, metabolic alkalosis, and arrhythmias.
• Progressive liver failure – from extensive hepatic metastases.
• Carcinoid crisis – rare, but massive hormone release can cause flushing, hypotension, and bronchospasm.
• Secondary cancers – patients with MEN‑1 have higher rates of pituitary, parathyroid, and bronchial NETs.

When to Seek Emergency Care

---

Sources: Mayo Clinic, National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), Cleveland Clinic, NEJM, Lancet Oncology, NETTER‑1 trial publications (2021), and peer‑reviewed neuroendocrine tumor guidelines (ENETS 2022).

```